These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 3130222)
41. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel. Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664 [TBL] [Abstract][Full Text] [Related]
42. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Dallenbach-Hellweg G Int J Gynecol Pathol; 1988; 7(1):95-6. PubMed ID: 3127347 [No Abstract] [Full Text] [Related]
43. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study. Nilsson CG; Allonen H; Diaz J; Luukkainen T Fertil Steril; 1983 Feb; 39(2):187-92. PubMed ID: 6401636 [TBL] [Abstract][Full Text] [Related]
44. Influences of copper and design of intrauterine devices on endometrial bleeding in monkeys. Shaw ST; Forino RV; Poon CH; Moyer DL Contraception; 1976 Jul; 14(1):9-15. PubMed ID: 824096 [TBL] [Abstract][Full Text] [Related]
45. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. Faundes A; Alvarez F; Brache V; Tejada AS Int J Gynaecol Obstet; 1988 Jun; 26(3):429-33. PubMed ID: 2900174 [TBL] [Abstract][Full Text] [Related]
46. The effects of intrauterine contraceptive devices on the ultrastructure of the endometrium in relation to bleeding complications. Sheppard BL; Bonnar J Am J Obstet Gynecol; 1983 Aug; 146(7):829-39. PubMed ID: 6869454 [TBL] [Abstract][Full Text] [Related]
47. Ultrastructural changes in human endometrium with copper and nonmedicated IUDs in utero. El-Badrawi HH; Hafez ES; Barnhart MI; Fayad M; Shafeek A Fertil Steril; 1981 Jul; 36(1):41-9. PubMed ID: 7250406 [TBL] [Abstract][Full Text] [Related]
48. Effect of single-dose, early luteal phase administration of mifepristone (RU486) on implantation stage endometrium in the rhesus monkey. Ghosh D; Sengupta J; Hendrickx AG Hum Reprod; 1996 Sep; 11(9):2026-35. PubMed ID: 8921085 [TBL] [Abstract][Full Text] [Related]
49. Ultrastructural comparative study on endometrium of Chinese women using intrauterine devices of stainless steel ring, copper T220, and releasing levonorgestrel: morphometry of microvessels. Wang JD; Zhu PD; Cheng J; Luo HZ; Xu RH; Hu WW Contraception; 1990 Apr; 41(4):389-97. PubMed ID: 2335103 [TBL] [Abstract][Full Text] [Related]
50. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles. Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585 [TBL] [Abstract][Full Text] [Related]
51. Immunolocalization of endothelin and neutral endopeptidase in the endometrium of users of subdermally implanted levonorgestrel (Norplant). Marsh MM; Butt AR; Riley SC; Rogers PA; Susil B; Affandi B; Findlay JK; Salamonsen LA Hum Reprod; 1995 Oct; 10(10):2584-9. PubMed ID: 8567775 [TBL] [Abstract][Full Text] [Related]
52. Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Brenner RM; Slayden OD; Nath A; Tsong YY; Sitruk-Ware R Contraception; 2010 Apr; 81(4):336-42. PubMed ID: 20227552 [TBL] [Abstract][Full Text] [Related]
53. mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. Rutanen EM; Salmi A; Nyman T Mol Hum Reprod; 1997 Sep; 3(9):749-54. PubMed ID: 9357999 [TBL] [Abstract][Full Text] [Related]
54. Uterine ultrasonographic changes during endometriosis treatment: a comparison between levonorgestrel-releasing intrauterine devices and a gonadotropin-releasing hormone agonist. Manetta LA; de Paula Martins W; Rosa e Silva JC; de Sá Rosa e Silva AC; Nogueira AA; Ferriani RA Ultrasound Med Biol; 2008 Dec; 34(12):1914-8. PubMed ID: 18597921 [TBL] [Abstract][Full Text] [Related]
55. Prostaglandin production in human endometrium following continuous exposure to low-dose levonorgestrel released from a vaginal ring. White JO; Sullivan MH; Patel L; Croxtall JD; d'Arcangues C; Belsey EM; Elder MG Contraception; 1991 Apr; 43(4):401-12. PubMed ID: 1649733 [TBL] [Abstract][Full Text] [Related]
56. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Milsom I; Andersson K; Andersch B; Rybo G Am J Obstet Gynecol; 1991 Mar; 164(3):879-83. PubMed ID: 1900665 [TBL] [Abstract][Full Text] [Related]
57. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Sturridge F; Guillebaud J Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696 [TBL] [Abstract][Full Text] [Related]
58. Endometrial vascular features prior to and following exposure to levonorgestrel. Hourihan HM; Sheppard BL; Belsey EM; Brosens IA Contraception; 1991 Apr; 43(4):375-85. PubMed ID: 1906793 [TBL] [Abstract][Full Text] [Related]